CureVac’s Market Exit: A New Chapter Begins Under BioNTech

CureVac NL0015436031

The independent stock market journey of German biotech firm CureVac has concluded. Following its acquisition by rival BioNTech, CureVac's shares have been suspended from trading, with a formal delisting from the Nasdaq now in effect. The company is being fully integrated into the BioNTech corporate structure. This move carries significant implications for shareholders and reshapes the European mRNA therapeutics landscape.

BioNTech has valued CureVac at approximately $1.25 billion in this all-stock transaction. For CureVac shareholders, the deal involved an exchange into BioNTech American Depositary Shares (ADSs), representing a value of about $5.46 per CureVac share. This price reflected a premium of roughly 55% over the volume-weighted three-month average share price of $3.53 prior to the initial offer announcement in June 2025.

The transaction received overwhelming support, ensuring a smooth integration path:
* By December 18, 2025, 86.75% of outstanding CureVac shares had been tendered.
* The remaining shares were transferred to BioNTech in early January through a compulsory acquisition mechanism.
* Major shareholders, including dievini Hopp BioTech and KfW, which together held a 13.32% stake, approved the deal.

Timeline of a Market Exit

The acquisition process reached its final stages in early January. Key milestones for the delisting include:
* January 6: Trading in CureVac stock was halted on the Nasdaq and other major exchanges prior to market open. This followed the completion of BioNTech's reorganization under the takeover terms. The final quoted price before suspension was $4.66 per share, marking an increase of around 40% since the deal was first announced.
* January 16: The official delisting from the Nasdaq takes effect.
* 90 days after SEC filing: The deregistration of CureVac's securities in the United States will become effective.

As part of the legal merger, the entity CureVac N.V. has been replaced by CureVac Merger B.V., with BioNTech now holding 100% of the operational business.

Strategic Gains for BioNTech

This acquisition provides BioNTech with several key strategic assets that bolster its long-term position:
* CureVac's manufacturing facility in Tübingen, Germany.
* Proprietary "RNA Printer" modules designed for automated mRNA production.
* CureVac's oncology-focused development pipeline.
* Over two decades of mRNA research expertise and the associated intellectual property portfolio.

These components significantly expand BioNTech's technological foundation and product portfolio, particularly in oncology and advanced manufacturing capabilities.

Leadership and Integration Plans

The entire previous CureVac management team has stepped down. Control of the company now rests fully with BioNTech's leadership. A new board has been established, featuring BioNTech CEO Prof. Ugur Sahin, alongside executives Sierk Poetting and Ramón Zapata-Gomez.

While day-to-day operations will continue initially, BioNTech is preparing a comprehensive strategic and scientific review of the combined organizations. Further details on integration plans are expected at the upcoming J.P. Morgan Healthcare Conference, where BioNTech will also address how it intends to utilize the newly acquired CureVac technologies.

Emerging Legal Challenges

Coinciding with the deal's closure, a new legal challenge has emerged for the mRNA sector. On January 6, Bayer filed a lawsuit in the United States against BioNTech, Pfizer, and Moderna.

The core allegation involves the infringement of Monsanto patents related to the stabilization of messenger RNA (mRNA). For BioNTech, this introduces additional complexity, as all of CureVac's existing legal obligations have now been transferred to the acquirer. Potential litigation and settlement costs could influence the strategic value derived from the transaction, a concern reflected in increased volatility for BioNTech's share price.

From Pandemic Contender to Acquisition Target

CureVac's time as a public company was brief but eventful. Early in the COVID-19 pandemic, the Tübingen-based firm was viewed as a potential key mRNA player alongside Moderna and BioNTech. However, clinical trial delays and manufacturing hurdles significantly tempered those early expectations.

Despite these operational setbacks, CureVac's underlying technology platform remained highly attractive. The BioNTech acquisition serves to secure these mRNA assets from competitors, strengthen BioNTech's patent library, and broaden its oncology research and production capacities. The outcome of this consolidation will be a defining factor for the future trajectory of the European mRNA industry.